Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PDC-APB in Urushiol-Sensitive Volunteers
NCT04853823Phase 1Unknown
- Sponsor
- Hapten Sciences
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
01
Overview
Phase 1, randomised, double-blind trial in poison ivy allergic contact dermatitis comparing PDC-APB with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events at 24 weeks. Status: unknown.
02
Drugs
PDC-APB
03
Conditions
poison ivy allergic contact dermatitis
Beyond the preview
Go deeper on NCT04853823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853823.